Eli Lilly Says Taltz Met Endpoints in Axial Spondyloarthritis Study
November 12 2019 - 8:28AM
Dow Jones News
By Michael Dabaie
Eli Lilly and Co. (LLY) said Taltz met the primary and all major
secondary endpoints in the COAST-X placebo-controlled Phase 3 study
in non-radiographic axial spondyloarthritis.
In the study, Taltz improved the signs and symptoms of
non-radiographic axSpA as measured by ASAS40, as well as reduced
inflammation on MRI, the company said.
Axial spondyloarthritis is a chronic inflammatory disease
affecting predominantly the sacroiliac joints and the spine
skeleton and is estimated to affect 4.5 million adults
worldwide.
A total of 303 adult patients with active nr-axSpA were
randomized to receive Taltz 80 mg subcutaneously every four weeks
or every two weeks, or placebo. At week 16, 35% of patients treated
every four weeks and 40% of patients treated every two weeks
achieved ASAS40 response, compared with 19% with placebo. At week
52, 30% treated every four weeks and 31% treated every two weeks
achieved ASAS40 response, compared with 13% with placebo.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 12, 2019 08:13 ET (13:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2023 to Sep 2024